Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016 (2016), Article ID 3196431, 9 pages
http://dx.doi.org/10.1155/2016/3196431
Research Article

Spironolactone Effect in Hepatic Ischemia/Reperfusion Injury in Wistar Rats

1Liver Unit, Department of Internal Medicine, University Hospital “Dr. José E. González”, The Autonomous University of Nuevo León, 64460 Monterrey, NL, Mexico
2Hospital Regional de Alta Especialidad de Ciudad Victoria “Bicentenario 2010”, 87087 Cuidad Victoria, TAMPS, Mexico
3Transplant Service, University Hospital “Dr. José E. González”, The Autonomous University of Nuevo León, 64460 Monterrey, NL, Mexico
4Department of Pathology, University Hospital “Dr. José E. González”, The Autonomous University of Nuevo León, 64460 Monterrey, NL, Mexico
5Department of Physiology, School of Medicine, The Autonomous University of Nuevo León, 64460 Monterrey, NL, Mexico

Received 24 July 2015; Revised 7 October 2015; Accepted 11 October 2015

Academic Editor: Karina R. Gordillo

Copyright © 2016 Julio César Jiménez Pérez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Jaeschke, “Role of reactive oxygen species in hepatic ischemia-reperfusion injury and preconditioning,” Journal of Investigative Surgery, vol. 16, no. 3, pp. 127–140, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. J. W. Kupiec-Weglinski and R. W. Busuttil, “Ischemia and reperfusion injury in liver transplantation,” Transplantation Proceedings, vol. 37, no. 4, pp. 1653–1656, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Pacher and G. Haskó, “Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning,” British Journal of Pharmacology, vol. 153, no. 2, pp. 252–262, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. N. R. Banga, S. Homer-Vanniasinkam, A. Graham, A. Al-Mukhtar, S. A. White, and K. R. Prasad, “Ischaemic preconditioning in transplantation and major resection of the liver,” The British Journal of Surgery, vol. 92, no. 5, pp. 528–538, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. G. J. Carrizo, R. Wu, X. Cui, A. J. Dwivedi, H. H. Simms, and P. Wang, “Adrenomedullin and adrenomedullin-binding protein-1 downregulate inflammatory cytokines and attenuate tissue injury after gut ischemia-reperfusion,” Surgery, vol. 141, no. 2, pp. 245–253, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Fondevila, R. W. Busuttil, and J. W. Kupiec-Weglinski, “Hepatic ischemia/reperfusion injury—a fresh look,” Experimental and Molecular Pathology, vol. 74, no. 2, pp. 86–93, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Jaeschke, “Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 284, no. 1, pp. G15–G26, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Pitt, F. Zannad, W. J. Remme et al., “The effect of spironolactone on morbidity and mortality in patients with severe heart failure,” The New England Journal of Medicine, vol. 341, no. 10, pp. 709–717, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Nishiyama and Y. Abe, “Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade,” Journal of Pharmacological Sciences, vol. 100, no. 1, pp. 9–16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Pitt, W. Remme, F. Zannad et al., “Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction,” The New England Journal of Medicine, vol. 348, no. 14, pp. 1309–1321, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. N. J. Brown, “Aldosterone and end-organ damage,” Current Opinion in Nephrology and Hypertension, vol. 14, no. 3, pp. 235–241, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. T. H. Hostetter and H. N. Ibrahim, “Aldosterone in chronic kidney and cardiac disease,” Journal of the American Society of Nephrology, vol. 14, no. 9, pp. 2395–2401, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. H. V. Joffe and G. K. Adler, “Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation,” Heart Failure Reviews, vol. 10, no. 1, pp. 31–37, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Batterink, S. N. Stabler, A. M. Tejani, and C. T. Fowkes, “Spironolactone for hypertension,” The Cochrane Database of Systematic Reviews, vol. 8, Article ID CD008169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. F. de Souza, E. Muxfeldt, R. Fiszman, and G. Salles, “Efficacy of spironolactone therapy in patients with true resistant hypertension,” Hypertension, vol. 55, no. 1, pp. 147–152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Liu, K. Hirooka, A. Nishiyama et al., “Activation of the aldosterone/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury,” Experimental Eye Research, vol. 96, no. 1, pp. 116–123, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. H. S. Ozacmak, V. H. Ozacmak, F. Barut, M. Arasli, and B. H. Ucan, “Pretreatment with mineralocorticoid receptor blocker reduces intestinal injury induced by ischemia and reperfusion: involvement of inhibition of inflammatory response, oxidative stress, nuclear factor κB, and inducible nitric oxide synthase,” The Journal of Surgical Research, vol. 191, no. 2, pp. 350–361, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Chai, I. M. Garrelds, R. de Vries, and A. H. J. Danser, “Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?” Hypertension, vol. 47, no. 4, pp. 665–670, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. M. Mejía-Vilet, V. Ramírez, C. Cruz, N. Uribe, G. Gamba, and N. A. Bobadilla, “Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone,” The American Journal of Physiology—Renal Physiology, vol. 293, no. 1, pp. F78–F86, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Dorrance, H. L. Osborn, R. Grekin, and R. C. Webb, “Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 281, no. 3, pp. R944–R950, 2001. View at Google Scholar · View at Scopus
  21. W.-Y. Lau, E. C. H. Lai, and S. H. Y. Lau, “Methods of vascular control technique during liver resection: a comprehensive review,” Hepatobiliary and Pancreatic Diseases International, vol. 9, no. 5, pp. 473–481, 2010. View at Google Scholar · View at Scopus
  22. E. K. Chouillard, A. A. Gumbs, and D. Cherqui, “Vascular clamping in liver surgery: physiology, indications and techniques,” Annals of Surgical Innovation and Research, vol. 4, article 2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. S. Yadav, D. Sindram, D. K. Perry, and P.-A. Clavien, “Ischemic preconditioning protects the mouse liver by inhibition of apoptosis through a caspase-dependent pathway,” Hepatology, vol. 30, no. 5, pp. 1223–1231, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. S.-Q. Shen, Y. Zhang, J.-J. Xiang, and C.-L. Xiong, “Protective effect of curcumin against liver warm ischemia/reperfusion injury in rat model is associated with regulation of heat shock protein and antioxidant enzymes,” World Journal of Gastroenterology, vol. 13, no. 13, pp. 1953–1961, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. Y.-X. Chen, M. Sato, K. Kawachi, and Y. Abe, “Neutrophil-mediated liver injury during hepatic ischemia-reperfusion in rats,” Hepatobiliary & Pancreatic Diseases International, vol. 5, no. 3, pp. 436–442, 2006. View at Google Scholar · View at Scopus
  26. K. M. Kurrelmeyer, Y. Ashton, J. Xu, S. F. Nagueh, G. Torre-Amione, and A. Deswal, “Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction,” Journal of Cardiac Failure, vol. 20, no. 8, pp. 560–568, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Ito, M. Mizuno, Y. Suzuki et al., “Long-term effects of spironolactone in peritoneal dialysis patients,” Journal of the American Society of Nephrology, vol. 25, no. 5, pp. 1094–1102, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Ojeda-Cervantes, J. Barrera-Chimal, J. Alberú, R. Pérez-Villalva, L. E. Morales-Buenrostro, and N. A. Bobadilla, “Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study,” American Journal of Nephrology, vol. 37, no. 5, pp. 481–490, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. M. J. Li, C. X. Huang, E. Okello, T. Yanhong, and S. Mohamed, “Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology,” The Canadian Journal of Cardiology, vol. 25, no. 9, pp. 523–526, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. N. C. Shah, S. D. Pringle, P. T. Donnan, and A. D. Struthers, “Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure,” Journal of Hypertension, vol. 25, no. 11, pp. 2345–2351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Casillas-Ramírez, I. B. Mosbah, F. Ramalho, J. Roselló-Catafau, and C. Peralta, “Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation,” Life Sciences, vol. 79, no. 20, pp. 1881–1894, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. Y.-M. Kang, Z.-H. Zhang, R. F. Johnson et al., “Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure,” Circulation Research, vol. 99, no. 7, pp. 758–766, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. P. R. Hansen, K. Rieneck, and K. Bendtzen, “Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells,” Immunology Letters, vol. 91, no. 2-3, pp. 87–91, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Datta, B. J. Fuller, and B. R. Davidson, “Molecular mechanisms of liver ischemia reperfusion injury: insights from transgenic knockout models,” World Journal of Gastroenterology, vol. 19, no. 11, pp. 1683–1698, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. C. A. Camargo Jr., J. F. Madden, W. Gao, R. S. Selvan, and P.-A. Clavien, “Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent,” Hepatology, vol. 26, no. 6, pp. 1513–1520, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. S.-Q. He, Y.-H. Zhang, S. K. Venugopal et al., “Delivery of antioxidative enzyme genes protects against ischemia/reperfusion-induced liver injury in mice,” Liver Transplantation, vol. 12, no. 12, pp. 1869–1879, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Rafatian, K. V. Westcott, R. A. White, and F. H. H. Leenen, “Cardiac macrophages and apoptosis after myocardial infarction: effects of central MR blockade,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 307, no. 7, pp. R879–R887, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. W.-F. Liu, S.-H. Wen, J.-H. Zhan et al., “Treatment with recombinant Trichinella spiralis cathepsin B-like protein ameliorates intestinal ischemia/reperfusion injury in mice by promoting a switch from M1 to M2 macrophages,” The Journal of Immunology, vol. 195, no. 1, pp. 317–328, 2015. View at Publisher · View at Google Scholar